Compare CSBR & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | ICG |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 97.1M |
| IPO Year | 1986 | 2023 |
| Metric | CSBR | ICG |
|---|---|---|
| Price | $7.57 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $7.50 |
| AVG Volume (30 Days) | 5.3K | ★ 76.8K |
| Earning Date | 03-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.43 |
| EPS | 0.17 | ★ 0.21 |
| Revenue | ★ $58,424,000.00 | $36,367,850.00 |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $11.51 | $75.98 |
| P/E Ratio | $44.07 | ★ $9.38 |
| Revenue Growth | ★ 9.06 | 6.53 |
| 52 Week Low | $5.59 | $0.93 |
| 52 Week High | $11.99 | $4.32 |
| Indicator | CSBR | ICG |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 54.66 |
| Support Level | $6.62 | $1.80 |
| Resistance Level | $7.45 | $2.28 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 88.39 | 44.57 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.